1Fe-LSD

# Research Output: 1Fe-LSD

**Generation Provenance ID:** 5b56dc06-4a5b-46e4-bed8-3cb9127a7dde  
**Research Date:** 2026-05-08  
**Substance Readiness:** Sparse/emerging — no dedicated peer-reviewed literature exists for 1Fe-LSD itself. All pharmacological data derives from class inference (N1-acyl LSD analog prodrug literature) and preclinical ferrocene safety literature. All 1Fe-LSD-specific claims are drawn from patent documentation, web-retrieved sources, and community reports.

---

## Chemical Identity

**IUPAC name:** (8β)-1-ferrocenecarbonyl-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide  
**Alternative systematic name:** 1-(ferrocenylcarbonyl)-lysergic acid diethylamide  
**Common name:** 1Fe-LSD  
**Code name:** SYN-L-234 (Synex Holdings BV internal designation)  
**CAS number:** 3029080-72-3  
**Molecular formula:** C₃₁H₃₃FeN₃O₂ (free base, MW ~535.5 g/mol) [Ref 9]  
— *Note: One web source (lsd-legal.de [Ref 13]) reports C₃₁H₃₄N₃O₂Fe at 536.46 g/mol; the discrepancy of 1 hydrogen unit likely reflects differing accounting of the ergoline ring system or protonation state. The hemi-L-tartrate salt form sold commercially will carry an additional mass contribution from the tartrate counter-ion.*  
**SMILES:** Not confirmed in any published or patent source; no PubChem entry exists as of May 2026.  
**InChIKey:** Not available in any source consulted.  
**PubChem CID:** None — compound not yet indexed.  
**Salt form sold:** Hemi-L-tartrate salt (orange to orange-brown powder/blotter/pellet).  

### Structural Features
1Fe-LSD is a member of the lysergamide (ergoline) chemical class in which the indole nitrogen at the N-1 position of the LSD scaffold bears a ferrocenecarbonyl substituent (—C(=O)—Fc, where Fc = ferrocene = [η⁵-C₅H₅]₂Fe). Ferrocene is an organometallic sandwich complex in which an iron(II) atom is coordinated between two cyclopentadienyl rings [Ref 11]. This substituent is substantially larger and more lipophilic than the acyl chains found in 1P-LSD, 1cP-LSD, 1V-LSD, and related analogs, and introduces an iron atom into the molecule — a structural novelty unprecedented among prior lysergamide designer drugs [Ref 9].

The ferrocene group is responsible for 1Fe-LSD's distinctive orange to orange-brown coloration in blotter and pellet formulations; this is not an indicator of contamination or oxidation but a characteristic spectroscopic property of the ferrocene chromophore [Ref 13].

### Seed Data Discrepancies
- The brief's seed data listed no SMILES, molecular formula, molecular weight, or InChIKey — confirmed absent from all published sources consulted.
- The brief listed no PubChem CID — confirmed: no PubChem entry exists.
- The brief listed no systematic name — established above from web-retrieved sources.
- **FLAG:** The molecular formula differs slightly between sources (535.5 vs. 536.46 g/mol). The generation agent should use 535.45 g/mol (C₃₁H₃₃FeN₃O₂, free base) as the canonical value pending a formal PubChem entry.

---

## Pharmacology

### Prodrug Mechanism
1Fe-LSD is presumed to act as a prodrug of lysergic acid diethylamide (LSD) via metabolic hydrolysis of the N-1 ferrocenecarbonyl ester bond, yielding LSD and ferrocenecarboxylic acid (FCA) as metabolic products [Ref 9, Ref 7]. This mechanism is established across the class of N1-acyl LSD analogs: Halberstadt et al. 2020 (Ref 1) demonstrated that ALD-52, 1P-LSD, and 1B-LSD are rapidly and efficiently deacylated in vivo (rat plasma) to yield LSD, and that this underlies their psychedelic activity. Brandt et al. 2020 (Ref 2) confirmed the same mechanism for 1CP-LSD via incubation with human serum. Brandt et al. 2025 (Ref 3) extended these findings to 1F-LSD (1-furan-2-carbonyl-LSD) and 1T-LSD.

For 1Fe-LSD specifically, Grokipedia (Ref 9) reports that LSD was detectable in mouse plasma within 30 minutes following intraperitoneal injection at 1 mg/kg, and that the compound induced the head-twitch response (HTR) in mice, an established preclinical assay for 5-HT₂A-mediated psychedelic activity. The source of this data is described as the patent WO2024028495A1 (Ref 7); however, the Google Patents retrieval of WO2024028495A1 did not yield explicit mention of SYN-L-234 or ferrocene-containing compounds, suggesting this data may come from a related but distinct patent or supplemental disclosure. **FLAG for verification: the preclinical HTR and PK data for 1Fe-LSD specifically require independent confirmation.**

### Primary Receptor Targets (by class inference from LSD)
LSD itself acts at multiple receptors. Based on Halberstadt et al. 2020 (Ref 1) and Cummins et al. 2025 (Ref 28):

- **5-HT₂A receptor** (primary psychedelic target): LSD is a partial agonist with high affinity. N1-acyl substitution reduces affinity at 5-HT₂A by 1–2 orders of magnitude (Halberstadt et al. 2020 [Ref 1]); these analogs likely serve as silent prodrugs at the receptor level, becoming active only after in vivo deacylation to LSD.
- **5-HT₂C receptor:** Partial agonist activity; contributes to appetite suppression and other effects.
- **5-HT₁A receptor:** Partial agonist activity.
- **Dopamine D₂ receptor:** Agonist with low-to-moderate affinity; contributes to some cognitive and perceptual effects.
- **Additional monoamine receptors** (α-adrenergic, histamine, etc.): Moderate affinities.

The 5-HT₂A "lid" mechanism: Wacker et al. 2017 (Ref 14) solved the crystal structure of LSD bound to 5-HT₂B, revealing that extracellular loop 2 (EL2) closes over the binding pocket like a lid after LSD enters, explaining LSD's exceptionally slow off-rate from 5-HT₂A and 5-HT₂B. This kinetic trap contributes to LSD's prolonged subjective effects relative to its plasma half-life and is expected to apply equally to LSD liberated from 1Fe-LSD in vivo.

No binding affinity (Ki or EC₅₀) data specific to 1Fe-LSD is available in any published source.

### Pharmacokinetics (LSD reference data; 1Fe-LSD not studied in humans)

The following PK parameters refer to LSD itself — the presumed active moiety after 1Fe-LSD hydrolysis. No human PK data exists for 1Fe-LSD.

- **Tmax:** ~1.1 h (Holze et al. 2021 [Ref 16], microdose study, 5–20 µg oral LSD)
- **Elimination half-life (t₁/₂):** ~2.7 h mean (range 1.5–6.2 h) (Holze et al. 2021 [Ref 16])
- **Primary CYP enzyme:** CYP2D6; poor metabolizers (PM) have ~75% higher LSD and OH-LSD AUC and longer half-lives vs. extensive metabolizers; CYP1A2 and CYP2C9 also involved but with no significant in vivo effect detected (Vizeli et al. 2021 [Ref 17])
- **Key metabolite:** 2-oxo-3-hydroxy-LSD (OH-LSD, also called nor-LSD) is the primary urinary metabolite detected in forensic analysis (Patton et al. 2024 [Ref 29])
- **Duration of effects vs. t₁/₂ discrepancy:** Despite the ~3 h half-life, subjective effects last 6.7–11 h at doses of 25–200 µg (Holze et al. 2021 [Ref 15]); the EL2 lid mechanism (Wacker et al. 2017 [Ref 14]) provides a structural explanation for prolonged receptor engagement.
- **Dose-proportional PK:** Confirmed across the 5–200 µg range (Holze et al. 2021 [Refs 15, 16])

### Prodrug Hydrolysis Kinetics (class context)
In the class, larger and more lipophilic N1 substituents exhibit slower or less efficient in vivo hydrolysis. Kavanagh et al. 2024 (Ref 6) demonstrated that 1DD-LSD (1-dodecanoyl-LSD) has 27-fold lower potency than LSD in the HTR assay, attributed to reduced hydrolysis efficiency with long-chain lipophilic acyl groups. The ferrocene group in 1Fe-LSD is substantially larger and more lipophilic than any acyl chain in prior analogs; the rate and efficiency of ferrocene carbonyl cleavage in human plasma or liver is unknown and cannot be reliably inferred from prior analogs. This has direct implications for onset, potency, and duration that cannot be determined without human studies.

---

## History

### Development
1Fe-LSD was developed within the research pipeline of Lizard Labs (officially Lizart Trading B.V. / Synex Synthetics B.V.), a Netherlands-based chemical producer and online vendor of research chemicals founded in 2012 in Maastricht. The company's founder, British chemist Alexander Stratford (pseudonym "Al"), was listed as inventor (alongside James Peter Bernard Williamson) on patent WO2024028495A1 [Ref 7], filed August 4, 2023, published February 8, 2024, and assigned to Synex Holdings BV.

The patent covers novel lysergamide prodrug derivatives broadly and describes extensive preclinical data for the SYN-L compound series; however, the patent's primary emphasis is on therapeutic lysergamide prodrugs with modulated hallucinogenic profiles, and SYN-L-234 (1Fe-LSD) is not explicitly named in the patent document retrieved from Google Patents. 1Fe-LSD appears to represent one of the last compounds developed before Lizard Labs announced its permanent closure effective December 31, 2024, citing increasing regulatory challenges in the Netherlands [Ref 11].

### Market Emergence
Following Lizard Labs' closure at the end of 2024, its catalog of novel lysergamide analogs continued to be distributed by affiliated or successor retailers in the European research chemical market. 1Fe-LSD appeared for sale beginning November 26, 2025 — five days after Germany's Bundesrat voted to prohibit its predecessor 1S-LSD (November 21, 2025), following an established pattern in which successor analogs are introduced to the German market within days of each new prohibition. 1Fe-LSD was sold initially as the hemi-L-tartrate salt in blotter form (200 µg/tab) and micropellets (300 µg/pill) [Ref 9, Ref 13].

### Regulatory History
The compound's introduction exploits the structural novelty of the ferrocene moiety, which does not fall within the ergoline-related structural classes explicitly prohibited under Germany's New Psychoactive Substances Act (NpSG) or the Federal Narcotics Act (BtMG) [Ref 25, Ref 13]. This is part of a sustained cat-and-mouse dynamic between novel lysergamide development and regulatory scheduling in the German market [Ref 8].

---

## Subjective Effects

**No controlled human studies have been conducted with 1Fe-LSD.** The following is inferred from LSD's documented effects (Holze et al. 2021 [Refs 15, 16]; Vollebregt et al. 2026 [Ref 30]) and community reports from Bluelight (December 2025, [Ref 12]).

Community reports describe effects as broadly comparable to 1P-LSD, 1S-LSD, and other prior lysergamide analogs — consistent with the prodrug model. One Bluelight thread (Ref 12) described the active dose as approximately 200 µg (matching the blotter formulation dose), with effects qualitatively similar to earlier lysergamide-series substances. The thread noted very limited firsthand accounts existed at the time of posting (December 2025), and the dominant discussion concerned theoretical toxicological risk rather than subjective experience.

### Effects inferred from LSD class (Holze et al. 2021 [Refs 15, 16]; Vollebregt et al. 2026 [Ref 30]):

**Perceptual:**
- Visual geometry, visual drifting, visual morphing, color enhancement, brightness alteration, tracers
- Synesthesia (dose-dependent)
- External and internal hallucinations at higher doses

**Cognitive:**
- Conceptual thinking, thought connectivity, creativity enhancement
- Pattern recognition enhancement
- Ego dissolution (dose-dependent, pronounced at ≥200 µg LSD equivalent)
- Thought loops; memory fragmentation at higher doses

**Emotional:**
- Emotional enhancement, euphoria, anxiety (dose-dependent)
- Significant anxiety and ego dissolution at ≥200 µg LSD equivalent (Holze et al. 2021 [Ref 15])

**Physiological:**
- Moderate increases in blood pressure and heart rate (Holze et al. 2021 [Ref 15])
- Pupil dilation; stimulation; muscle tension

### Duration (LSD class reference, Holze et al. 2021 [Ref 15]):
- 25 µg LSD: ~6.7 h total subjective effect duration
- 100 µg LSD: ~9–10 h
- 200 µg LSD: ~11 h

For 1Fe-LSD, the duration will additionally depend on the kinetics of ferrocene carbonyl cleavage, which is unknown. If hydrolysis is slower than in other N1-acyl analogs, onset may be delayed and duration extended. **FLAG: No 1Fe-LSD-specific duration data exists; generation agent should present all duration figures as class-inferred from LSD.**

---

## Safety & Toxicity

### General LSD Class Safety
LSD itself has an extremely low acute toxicity profile. Nichols & Grob 2018 (Ref 18) reviewed five LSD-attributed deaths and concluded that deaths directly attributable to LSD alone are exceedingly rare; most reported deaths involved adulterants, particularly 25I-NBOMe sold as LSD. EUDA notes that overdose deaths from LSD are "virtually unknown" (Ref — EUDA web source).

For LSD analogs generally, Jurowski et al. 2026 (Ref 4) conducted multi-platform in silico toxicity prediction for five N1-acyl LSD analogs (ALD-52, 1P-LSD, 1B-LSD, 1V-LSD, 1cP-LSD), finding predicted rat LD₅₀ values of 49–85 mg/kg, with elevated cardiotoxicity and genotoxicity alerts for 1cP-LSD specifically. N1-acyl position modification was found to influence toxicity patterns.

### Ferrocene-Specific Safety Concerns — CRITICAL FLAG

**1Fe-LSD introduces a structurally unprecedented ferrocene (organometallic iron) moiety into the lysergamide class. The following concerns are supported by published literature but have NOT been investigated for 1Fe-LSD specifically:**

#### Brain Iron Loading (Published Animal Data)
Ward et al. 1995 (Ref 20) administered the ferrocene derivative 3,5,5-trimethyl hexanoyl ferrocene to rats for 4 weeks and found **up to 50% increase in iron content** in the substantia nigra, cerebellum, and cerebral cortex. Subsequent chelation with hydroxypyridones or desferrioxamine reduced brain iron content, and dopamine metabolism was significantly altered (homovanillic acid and dopamine turnover). This is the most directly relevant published animal study for the safety of brain-penetrant ferrocene-containing compounds.

#### Fenton Chemistry Risk (Theoretical, Community-Raised)
The Bluelight community discussion (Ref 12, Ref 26) raised concerns that 1Fe-LSD's high lipophilicity allows it to cross the blood-brain barrier (BBB) intact before hydrolysis, effectively delivering the iron-containing ferrocene moiety to the CNS. Iron cycling between Fe²⁺/Fe³⁺ states catalyzes the Fenton reaction (Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻), generating hydroxyl radicals capable of causing lipid peroxidation, protein oxidation, and potentially triggering ferroptosis. Because iron acts as a catalyst (not consumed), a single iron atom could theoretically generate many ROS events. Chronic brain iron excess and resulting neuroinflammation are established risk factors for neurodegenerative disease.

#### In Silico Toxicity Predictions for 1Fe-LSD (Computational, Not Experimental)
Web-retrieved community sources (Ref 26) report the following computational toxicity predictions from ProTox-3.0 and ADMETlab 2.0 for 1Fe-LSD specifically:
- **Neurotoxicity** (ProTox-3.0): 77% probability ("neuro Active")
- **Immunotoxicity** (ProTox-3.0): 99% probability ("immuno Active")
- **Mitochondrial membrane potential disruption** (SR-MMP): 88% probability
- **Drug-induced liver injury** (DILI, ADMETlab 2.0): 0.808 (high risk)
- **BBB penetration** as intact prodrug: 92% probability (consistent with high lipophilicity)

**These are computational predictions, not experimental data. In silico models are known to overpredict toxicity for structurally unusual compounds and have not been validated for organometallic drug scaffolds. They do not constitute clinical or experimental evidence of toxicity, but they raise a meaningful prior concern warranting empirical investigation before widespread human use.**

#### Counter-Argument: FCA Metabolite Safety
A counterpoint raised in community discussions (Ref 26) and vendor materials (Ref 9, 13) is that the metabolic product ferrocenecarboxylic acid (FCA) is described as:
- Non-mutagenic (Ames test negative)
- Non-carcinogenic
- Of negligible acute toxicity

However, **no published peer-reviewed data confirming FCA safety at CNS-relevant concentrations, or investigating whether ferrocene-to-FCA conversion occurs exclusively in the periphery vs. the CNS, was identified in this research.** This remains an unresolved safety question.

#### No Reported Adverse Events
No case reports, emergency department presentations, or adverse event reports for 1Fe-LSD were identified in any published source as of May 2026. The substance has been on the market for fewer than 6 months, and the total number of human exposures is unknown.

### LD₅₀ and Therapeutic Index
No LD₅₀ data for 1Fe-LSD exists in any published source. By class analogy with other N1-acyl LSD analogs (Jurowski et al. 2026 [Ref 4]: predicted rat LD₅₀ 49–85 mg/kg), and with LSD itself (estimated LD₅₀ in rats >16 mg/kg, effective dose in humans ~100 µg = 0.1 mg/kg), therapeutic indices for the LSD class are very wide. However, **the ferrocene moiety introduces an unknown variable not present in any prior analog** — the potential for organ-specific toxicity from iron loading cannot be predicted from the LSD class LD₅₀ literature.

### Psychological Risks
By class inference from LSD:
- Acute anxiety, panic, and confusion (dose-dependent; prominent at higher doses)
- Psychosis-like states in predisposed individuals
- HPPD Types I and II (Martinotti et al. 2018 [Ref 22]; Müller et al. 2022 [Ref 23])
- Suicidal ideation (rare, typically in context of difficult experiences or pre-existing psychopathology)

---

## Harm Reduction

No 1Fe-LSD-specific harm reduction guidelines exist in any published source. All recommendations below are inferred from LSD class literature and general psychedelic harm reduction principles.

**Specific 1Fe-LSD harm reduction concern:** Given the unresolved questions about ferrocene iron loading in the CNS (Ward et al. 1995 [Ref 20]) and the complete absence of human pharmacokinetic and safety data, **this compound's safety profile cannot be assumed to mirror prior N1-acyl LSD analogs.** The Bluelight community discussion (Ref 12) included expert-level commentary calling 1Fe-LSD "toxicologically unjustifiable as a consumer product" pending empirical data — a position that should be prominently surfaced in any article.

**Testing:** Standard LSD reagent tests (Ehrlich reagent: purple-positive for indole alkaloids) should react to 1Fe-LSD given the indole core. The distinctive orange color of authentic 1Fe-LSD is a visual indicator but not a purity guarantee. No 1Fe-LSD-specific reagent testing protocol has been published. HPLC or mass spectrometry is required for identification (Tusiewicz et al. 2024 [Ref 5] established GC-MS methodology for the LSD analog class; 1Fe-LSD was not specifically included in that paper's analyte set).

**Set and setting, dosage caution, avoiding combinations:** Standard psychedelic harm reduction recommendations apply. Given the 200–300 µg formulation doses, users should understand these represent strong-to-very strong LSD-equivalent doses pending clarification of prodrug efficiency.

**Contraindications by class inference:** Personal or family history of psychosis or schizophrenia; current use of lithium (increased seizure risk with LSD class); combination with MAOIs (significantly potentiated/unpredictable effects); current SSRI/SNRI use (attenuated effects, small serotonin syndrome risk).

---

## Tolerance & Dependence

No 1Fe-LSD-specific tolerance or dependence data exists.

**Tolerance (by class inference):**
LSD produces rapid tolerance (tachyphylaxis) within the serotonergic psychedelic class, mediated primarily through 5-HT₂A receptor downregulation in the frontal cortex (de la Fuente Revenga et al. 2022 [Ref 21]). Repeated administration causes a progressive decrease in the head-twitch response, and cross-tolerance develops between LSD and other 5-HT₂A agonist psychedelics. Tolerance to psychedelics develops acutely (within 1–4 days of repeated use) and resolves over approximately 2 weeks with abstinence.

The mechanism is independent of β-arrestin-2 signaling (de la Fuente Revenga et al. 2022 [Ref 21]). Cross-tolerance is not seen with non-psychedelic 5-HT₂A agonists such as lisuride, suggesting that tolerance is psychedelic-specific and not simply receptor downregulation.

**Dependence and withdrawal:**
LSD does not produce physical dependence or a clinically recognized withdrawal syndrome. Psychological compulsion is uncommon given the rapid tolerance development. No dependence liability data exists for 1Fe-LSD specifically, and the LSD class as a whole has minimal addiction potential.

---

## Interactions

No 1Fe-LSD-specific drug interaction studies exist. All data below is inferred from LSD and the LSD analog class.

**MAOIs:** Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline, harmine/harmaline) inhibit the enzymatic breakdown of serotonin and monoamines, potentially intensifying and prolonging the effects of serotonergic psychedelics. Combined use is considered high-risk. Malcolm & Thomas 2022 (Ref 19) reviewed serotonin toxicity risks in this context; full serotonin syndrome is theoretically possible but rare with LSD alone even with MAOI co-administration.

**SSRIs/SNRIs:** Serotonin reuptake inhibitors typically attenuate the subjective effects of LSD via 5-HT₂A receptor downregulation from chronic serotonergic stimulation. Acute combined use carries a theoretical serotonin syndrome risk that is generally considered low with LSD-class drugs specifically (Malcolm & Thomas 2022 [Ref 19]).

**CYP2D6 inhibitors:** Because CYP2D6 is the primary enzyme metabolizing LSD (Vizeli et al. 2021 [Ref 17]), strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) may substantially increase LSD exposure and prolong effects. This interaction is expected to apply to the LSD released from 1Fe-LSD after hydrolysis.

**Lithium:** Combination of LSD with lithium has been associated with seizures in multiple case reports in the literature. **This interaction is considered a contraindication for the LSD class.**

**Antipsychotics:** 5-HT₂A antagonists (e.g., risperidone, quetiapine, olanzapine) are expected to attenuate or abort psychedelic effects and may be used in acute adverse event management.

**Stimulants:** Combined use with amphetamines, MDMA, or cocaine increases cardiovascular risk and may intensify adverse psychological effects.

**Cannabis:** Often reported to intensify and prolong psychedelic effects; may increase risk of anxiety and paranoia.

**Tramadol:** Serotonergic activity of tramadol combined with a serotonergic psychedelic raises serotonin syndrome risk.

**FLAG:** No interaction data is specific to 1Fe-LSD. The ferrocene moiety's potential interactions with iron-chelating drugs, redox-active medications, or hepatic metabolism pathways are unknown and uninvestigated.

---

## Legal Status

**Germany:** As of early 2026, 1Fe-LSD is not prohibited under the Neue-psychoaktive-Stoffe-Gesetz (NpSG), the Betäubungsmittelgesetz (BtMG), or the Arzneimittelgesetz (AMG). The ferrocene moiety does not fall within any ergoline-related structural class explicitly covered by these laws [Ref 13, Ref 25]. 1Fe-LSD's introduction to the German market on November 26, 2025, was timed immediately after the prohibition of its predecessor 1S-LSD.

**United Kingdom:** Not controlled under the Misuse of Drugs Act 1971. The UK Psychoactive Substances Act 2016 prohibits supply of psychoactive substances but exempts personal possession; legal status for personal use is reportedly legal as of February 2026 [Ref 25].

**United States:** Not explicitly listed in the Controlled Substances Act schedules. The Federal Analogue Act (FAA, 21 U.S.C. § 813) may apply if 1Fe-LSD is intended for human consumption and is substantially similar in chemical structure and pharmacological effect to a Schedule I controlled substance (LSD is Schedule I). However, FAA applicability is prosecutorially determined and is not a definitive scheduling. **FLAG: US legal status requires attorney review; the generation agent should not state this compound is definitively "legal" in the US.**

**Canada:** Not explicitly listed under the Controlled Drugs and Substances Act as of early 2026 [Ref 9, Ref 25].

**International:** Not scheduled under the United Nations 1971 Convention on Psychotropic Substances. LSD (the active moiety after hydrolysis) is Schedule I under that convention, which may bear on analogy-based enforcement in some jurisdictions.

**Australia/New Zealand:** Not specifically researched; likely captured under analogue provisions similar to the US FAA. **FLAG: Australian/NZ legal status not confirmed by any source consulted.**

---

## Clinical Trials

No clinical trials for 1Fe-LSD have been registered on ClinicalTrials.gov as of May 2026. The compound has been available for fewer than 6 months and has no IND or human volunteer trial history.

### Active/Completed LSD Trials (class context)
The following trials investigate LSD itself, which is the presumed active moiety of 1Fe-LSD, providing relevant pharmacological and safety context:

- **NCT05674669** — Dose-Ranging Study of 50–100 µg LSD in Healthy Volunteers (Phase 1, Eleusis Therapeutics; COMPLETED)
- **NCT04227756** — Comparative Acute Effects of LSD, Psilocybin and Mescaline (Phase 1, University Hospital Basel; COMPLETED)
- **NCT05477459** — LSD to Improve Cluster Headache Impact Trial (Phase 2, Radboud University Medical Center; RECRUITING)
- **NCT03866252** — LSD Therapy for Persons Suffering From Major Depression (Phase 2, University Hospital Basel; COMPLETED)
- **NCT07189299** — Microdosing LSD in Women With Premenstrual Disorders (Phase N/A, Holze; NOT YET RECRUITING)

These trials involve pharmaceutical-grade LSD (not 1Fe-LSD) and cannot substitute for 1Fe-LSD-specific human safety and efficacy studies.

---

## Community Feedback Analysis

No community feedback was submitted in the brief's Part A2 section.

> No community feedback submitted.

---

## Gaps & Flags

The following are unresolved issues, missing data, and safety-critical values that the generation agent and human editors must treat with care:

### CRITICAL FLAGS

1. **Ferrocene BBB/brain iron concern — unresolved empirically for 1Fe-LSD.** Ward et al. 1995 [Ref 20] demonstrated that ferrocene derivatives cause up to 50% brain iron increase in rats after 4 weeks. Whether 1Fe-LSD, at human recreational doses and frequencies, produces meaningful brain iron loading is unknown. This should be clearly stated as an open safety question.

2. **In silico toxicity predictions (neurotoxicity 77%, immunotoxicity 99%, DILI 80.8%) are computational only.** These figures are from ProTox-3.0 and ADMETlab 2.0 and were retrieved from community sources (Ref 26), not peer-reviewed publications. They should be cited with appropriate hedging and labelled as predictive model outputs, not experimental findings.

3. **No human pharmacokinetic data for 1Fe-LSD.** Dose ranges, onset, peak, and duration cannot be stated with substance-specific confidence. All such data is either LSD-class inference or based on the commercial formulation doses (200 µg blotter, 300 µg micropellet).

4. **Ferrocene carbonyl hydrolysis efficiency is unknown.** The prodrug activation rate for the ferrocenecarbonyl ester bond has not been measured in human plasma, liver microsomes, or in vivo. Potency relative to LSD is therefore unknown. The 200–300 µg commercial dosing may reflect overcompensation for incomplete hydrolysis, or may represent a genuinely high-dose formulation intended to match LSD-equivalent psychedelic effects.

5. **FCA safety at CNS-relevant concentrations is unconfirmed.** The claim that ferrocenecarboxylic acid is non-mutagenic and non-carcinogenic is stated in vendor/community sources without a published peer-reviewed primary reference.

6. **No peer-reviewed literature exists on 1Fe-LSD specifically.** The compound does not appear in PubMed, OpenAlex, or PubChem as of May 2026. All pharmacological claims are structural-analog inferences or web-retrieved data of limited verifiability.

7. **US legal status under Federal Analogue Act.** Not definitively established. Should not be stated as "legal" — correct framing is "not explicitly scheduled."

8. **Patent WO2024028495A1 does not explicitly name SYN-L-234 / ferrocene-LSD.** The preclinical HTR and plasma LSD data attributed to 1Fe-LSD in some web sources (Ref 9) may originate from a different disclosure. The specific preclinical evidence cited should be flagged as needing primary source verification.

9. **Australian, New Zealand, and most European country-specific legal status not confirmed** beyond the general statement that 1Fe-LSD is not scheduled under the 1971 UN Convention.

10. **Molecular weight discrepancy (535.5 vs. 536.46 g/mol):** Likely a salt-form vs. free-base difference. Generation agent should use 535.45 g/mol (free base) pending PubChem indexing.

### DATA GAPS

- No SMILES, InChIKey, or PubChem CID
- No melting point, solubility, or other physical property data
- No human dose-response data
- No human pharmacokinetic data for 1Fe-LSD itself
- No receptor binding affinity (Ki/EC₅₀) data for 1Fe-LSD
- No metabolic pathway data for ferrocene carbonyl cleavage in humans
- No reported adverse events or case reports
- No independent analytical characterization (e.g., NMR, mass spectra) in any published peer-reviewed source
- No HPPD or other long-term psychological effect data
- No direct CYP enzyme data for 1Fe-LSD (class inference: CYP2D6 expected for the LSD moiety, but CYP involvement in ferrocene carbonyl cleavage is unknown)